Fusobacteriumnucleatum Adheres to Clostridioides difficile via the RadD Adhesin to Enhance Biofilm Formation in Intestinal Mucus.


Journal

Gastroenterology
ISSN: 1528-0012
Titre abrégé: Gastroenterology
Pays: United States
ID NLM: 0374630

Informations de publication

Date de publication:
03 2021
Historique:
received: 05 10 2019
revised: 02 11 2020
accepted: 13 11 2020
pubmed: 24 11 2020
medline: 6 8 2021
entrez: 23 11 2020
Statut: ppublish

Résumé

Although Clostridioides difficile infection (CDI) is known to involve the disruption of the gut microbiota, little is understood regarding how mucus-associated microbes interact with C difficile. We hypothesized that select mucus-associated bacteria would promote C difficile colonization and biofilm formation. To create a model of the human intestinal mucus layer and gut microbiota, we used bioreactors inoculated with healthy human feces, treated with clindamycin and infected with C difficile with the addition of human MUC2-coated coverslips. C difficile was found to colonize and form biofilms on MUC2-coated coverslips, and 16S rRNA sequencing showed a unique biofilm profile with substantial cocolonization with Fusobacterium species. Consistent with our bioreactor data, publicly available data sets and patient stool samples showed that a subset of patients with C difficile infection harbored high levels of Fusobacterium species. We observed colocalization of C difficile and F nucleatum in an aggregation assay using adult patients and stool of pediatric patients with inflammatory bowel disease and in tissue sections of patients with CDI. C difficile strains were found to coaggregate with F nucleatum subspecies in vitro; an effect that was inhibited by blocking or mutating the adhesin RadD on Fusobacterium and removal of flagella on C difficile. Aggregation was shown to be unique between F nucleatum and C difficile, because other gut commensals did not aggregate with C difficile. Addition of F nucleatum also enhanced C difficile biofilm formation and extracellular polysaccharide production. Collectively, these data show a unique interaction of between pathogenic C difficile and F nucleatum in the intestinal mucus layer.

Sections du résumé

BACKGROUND & AIMS
Although Clostridioides difficile infection (CDI) is known to involve the disruption of the gut microbiota, little is understood regarding how mucus-associated microbes interact with C difficile. We hypothesized that select mucus-associated bacteria would promote C difficile colonization and biofilm formation.
METHODS
To create a model of the human intestinal mucus layer and gut microbiota, we used bioreactors inoculated with healthy human feces, treated with clindamycin and infected with C difficile with the addition of human MUC2-coated coverslips.
RESULTS
C difficile was found to colonize and form biofilms on MUC2-coated coverslips, and 16S rRNA sequencing showed a unique biofilm profile with substantial cocolonization with Fusobacterium species. Consistent with our bioreactor data, publicly available data sets and patient stool samples showed that a subset of patients with C difficile infection harbored high levels of Fusobacterium species. We observed colocalization of C difficile and F nucleatum in an aggregation assay using adult patients and stool of pediatric patients with inflammatory bowel disease and in tissue sections of patients with CDI. C difficile strains were found to coaggregate with F nucleatum subspecies in vitro; an effect that was inhibited by blocking or mutating the adhesin RadD on Fusobacterium and removal of flagella on C difficile. Aggregation was shown to be unique between F nucleatum and C difficile, because other gut commensals did not aggregate with C difficile. Addition of F nucleatum also enhanced C difficile biofilm formation and extracellular polysaccharide production.
CONCLUSIONS
Collectively, these data show a unique interaction of between pathogenic C difficile and F nucleatum in the intestinal mucus layer.

Identifiants

pubmed: 33227279
pii: S0016-5085(20)35437-8
doi: 10.1053/j.gastro.2020.11.034
pmc: PMC7956072
mid: NIHMS1648624
pii:
doi:

Substances chimiques

Adhesins, Bacterial 0
MUC2 protein, human 0
Mucin-2 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1301-1314.e8

Subventions

Organisme : NIAID NIH HHS
ID : U01 AI124290
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK123704
Pays : United States
Organisme : NIAID NIH HHS
ID : F32 AI136404
Pays : United States
Organisme : NIDDK NIH HHS
ID : K01 DK123195
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI123278
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK056338
Pays : United States

Informations de copyright

Copyright © 2021 AGA Institute. Published by Elsevier Inc. All rights reserved.

Références

N Engl J Med. 2015 Jul 16;373(3):287-8
pubmed: 26176396
Infect Immun. 2015 Nov;83(11):4383-91
pubmed: 26324536
PLoS One. 2007 Aug 01;2(7):e659
pubmed: 17668047
Genome Med. 2016 Apr 27;8(1):47
pubmed: 27121861
Infect Immun. 2014 Jul;82(7):2815-25
pubmed: 24733099
Eur J Cancer Prev. 2001 Aug;10(4):313-21
pubmed: 11535873
J Mol Biol. 2016 Aug 28;428(17):3355-71
pubmed: 27170548
Sci Transl Med. 2018 Oct 24;10(464):
pubmed: 30355801
mBio. 2014 May 06;5(3):e01021-14
pubmed: 24803517
Nat Rev Microbiol. 2010 Apr;8(4):290-5
pubmed: 20234377
Sci Data. 2017 Oct 17;4:170152
pubmed: 29039846
Ann Lab Med. 2016 Jul;36(4):387-9
pubmed: 27139617
Nucleic Acids Res. 2017 Jan 4;45(D1):D535-D542
pubmed: 27899627
Mol Microbiol. 2009 Jan;71(1):35-47
pubmed: 19007407
Microb Ecol. 2012 Apr;63(3):532-42
pubmed: 22202886
Nat Rev Microbiol. 2019 Mar;17(3):156-166
pubmed: 30546113
Inflamm Bowel Dis. 2013 Sep;19(10):2223-6
pubmed: 23929262
Cell Mol Gastroenterol Hepatol. 2019;8(2):209-229
pubmed: 31029854
PLoS One. 2018 Aug 13;13(8):e0197649
pubmed: 30102706
Am J Physiol Gastrointest Liver Physiol. 2015 Mar 15;308(6):G510-24
pubmed: 25552581
Gastroenterology. 2011 Nov;141(5):1762-72
pubmed: 21889923
Infect Immun. 2013 Oct;81(10):3757-69
pubmed: 23897605
Aliment Pharmacol Ther. 2016 Oct;44(7):715-727
pubmed: 27481036
Environ Microbiol. 2018 Apr;20(4):1419-1435
pubmed: 29349925
Appl Environ Microbiol. 2012 Dec;78(24):8703-11
pubmed: 23042171
Cell Host Microbe. 2016 Aug 10;20(2):215-25
pubmed: 27512904
Infect Immun. 2014 Jan;82(1):193-201
pubmed: 24126525
J Med Microbiol. 1994 Nov;41(5):319-23
pubmed: 7966203
Infect Control Hosp Epidemiol. 2014 Sep;35 Suppl 2:S48-65
pubmed: 25376069
mBio. 2019 Jun 18;10(3):
pubmed: 31213556
Braz J Microbiol. 2015 Oct-Dec;46(4):1135-40
pubmed: 26691472
Mol Microbiol. 2006 Jan;59(1):142-51
pubmed: 16359324
Inflamm Bowel Dis. 2011 Sep;17(9):1971-8
pubmed: 21830275
Microbiologyopen. 2014 Oct;3(5):729-51
pubmed: 25155235
J Crohns Colitis. 2019 Jan 1;13(1):27-38
pubmed: 30247650
Caries Res. 2008;42(5):380-6
pubmed: 18781066
mBio. 2012 May 15;3(3):
pubmed: 22589288
J Microbiol Methods. 2003 Oct;55(1):315-9
pubmed: 14500024

Auteurs

Melinda A Engevik (MA)

Department of Pathology and Immunology, Baylor College of Medicine, Houston, Texas; Texas Children's Microbiome Center, Department of Pathology, Texas Children's Hospital, Houston, Texas. Electronic address: melinda.engevik@bcm.edu.

Heather A Danhof (HA)

Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas.

Jennifer Auchtung (J)

Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas; Department of Food Science and Technology, University of Nebraska-Lincoln, Lincoln, Nebraska.

Bradley T Endres (BT)

Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, Texas.

Wenly Ruan (W)

Department of Pathology and Immunology, Baylor College of Medicine, Houston, Texas; Texas Children's Microbiome Center, Department of Pathology, Texas Children's Hospital, Houston, Texas.

Eugénie Bassères (E)

Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, Texas.

Amy C Engevik (AC)

Department of Surgical Sciences, Vanderbilt University Medical Center, Nashville, Tennessee.

Qinglong Wu (Q)

Department of Pathology and Immunology, Baylor College of Medicine, Houston, Texas; Texas Children's Microbiome Center, Department of Pathology, Texas Children's Hospital, Houston, Texas.

Maribeth Nicholson (M)

Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee.

Ruth Ann Luna (RA)

Department of Pathology and Immunology, Baylor College of Medicine, Houston, Texas; Texas Children's Microbiome Center, Department of Pathology, Texas Children's Hospital, Houston, Texas.

Kevin W Garey (KW)

Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, Texas.

Sue E Crawford (SE)

Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas.

Mary K Estes (MK)

Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas; Department of Surgical Sciences, Vanderbilt University Medical Center, Nashville, Tennessee.

Renate Lux (R)

Department of Periodontics, University of California Los Angeles School of Dentistry, Los Angeles, California.

Mary Beth Yacyshyn (MB)

Department of Medicine Division of Digestive Diseases University of Cincinnati College of Medicine, Cincinnati, Ohio.

Bruce Yacyshyn (B)

Department of Medicine Division of Digestive Diseases University of Cincinnati College of Medicine, Cincinnati, Ohio.

Tor Savidge (T)

Department of Pathology and Immunology, Baylor College of Medicine, Houston, Texas; Texas Children's Microbiome Center, Department of Pathology, Texas Children's Hospital, Houston, Texas.

Robert A Britton (RA)

Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas.

James Versalovic (J)

Department of Pathology and Immunology, Baylor College of Medicine, Houston, Texas; Texas Children's Microbiome Center, Department of Pathology, Texas Children's Hospital, Houston, Texas.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH